4516.T Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 22:27):

Stats
Today's Volume	57 800.00
Average Volume	337 968
Market Cap	288.20B
EPS	¥0 ( 2024-02-08 )
Next earnings date	( ¥39.17 ) 2024-05-09
Last Dividend	¥57.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	11.94
ATR14	¥2.67 (0.06%)

Volume Correlation

Long: 0.21 (neutral)

Short: 0.89 (strong)

Signal:(55.13) Same movement expected

Nippon Shinyaku Co., Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nippon Shinyaku Co., Ltd. Correlation - Currency/Commodity

-0.74
( moderate negative )

-0.79
( moderate negative )

0.38
( neutral )

-0.68
( moderate negative )

0.06
( neutral )

0.42
( neutral )

Nippon Shinyaku Co., Ltd. Financials

Annual	2022
Revenue:	¥144.18B
Gross Profit:	¥88.20B (61.17 %)
EPS:	¥338.70

Q3	2023
Revenue:	¥39.41B
Gross Profit:	¥26.12B (66.28 %)
EPS:	¥116.20

Q2	2023
Revenue:	¥36.30B
Gross Profit:	¥23.94B (65.96 %)
EPS:	¥110.26

Q1	2023
Revenue:	¥37.01B
Gross Profit:	¥24.05B (64.98 %)
EPS:	¥129.90

Financial Reports:

No articles found.

Nippon Shinyaku Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥57.00 (N/A)	¥0 (N/A)	¥57.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Nippon Shinyaku Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.77 - Stable (15.39%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥5.00	2001-03-27
Last Dividend	¥57.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	45	--
Total Paid Out	¥829.00	--
Avg. Dividend % Per Year	0.00%	--
Score	4.38	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.77
Div. Directional Score	9.75	--

Next Divdend (Est)
(2024-07-22)

¥0 Estimate 0.00 %

Dividend Stability

0.10 Very Bad

Dividend Score

4.38

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8541.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
7864.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7004.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
6357.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
5214.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%
4319.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
3486.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
2715.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
9612.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
8153.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.164	1.500	6.72	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0974	1.200	6.75	8.10	[0 - 0.3]
returnOnEquityTTM	0.117	1.500	9.81	10.00	[0.1 - 1]
payoutRatioTTM	0.331	-1.000	6.69	-6.69	[0 - 1]
currentRatioTTM	5.92	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.17	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.11	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00826	-1.500	9.86	-10.00	[0 - 0.6]
interestCoverageTTM	264.20	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	321.86	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	163.50	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00953	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.646	1.000	2.57	2.57	[0.2 - 0.8]
operatingProfitMarginTTM	0.226	1.000	7.47	7.47	[0.1 - 0.6]
cashFlowToDebtRatioTTM	10.59	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.593	0.800	9.38	7.50	[0.5 - 2]
Total Score				13.73

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	12.08	1.000	8.88	0	[1 - 100]
returnOnEquityTTM	0.117	2.50	9.88	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	163.50	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.87	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	321.86	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.331	1.500	6.69	-6.69	[0 - 1]
pegRatioTTM	-1.977	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.147	1.000	8.81	0	[0.1 - 0.5]
Total Score				5.77

Nippon Shinyaku Co., Ltd.

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.